Founded in 2021, Precision has made significant strides, including developing a minimally invasive BCI system, testing it on 27 patients, and securing FDA Breakthrough Device designation. The company has also expanded its team and acquired a manufacturing facility in Texas. Precision's technology is designed to be safely removable and capable of processing large amounts of neural data, with the potential to address a wide range of neurological disorders. The company is led by a team that includes Ben Rapoport, a former co-founder of Neuralink, and aims to connect human intelligence with artificial intelligence.
Key takeaways:
```html
- Precision Neuroscience raised $102 million in a Series C funding round, bringing its total funding to $155 million, making it one of the best-funded brain–computer interface companies.
- The funding will be used to advance clinical research and develop AI-powered brain implants designed to help paralyzed individuals operate computers with their thoughts.
- Precision's brain–computer interface technology aims to address various neurological conditions, with potential applications beyond motor paralysis.
- The company has achieved significant milestones, including FDA Breakthrough Device designation and successful testing of its device in 27 patients.